Landmark Study Validates AI for Opioid Disorder Treatment
A peer-reviewed study in PNAS reports that GATC-1021, an AI-identified small molecule modulating 5-HT2A and 5-HT6 receptors, reduced fentanyl...
Jon Napitupulu
Nervgen’s Successful FDA Meeting Sparks Phase 3 Trial Hope
NVG-291 produced a mean 3.7-point gain on GRASSP Quantitative Prehension at Week 12 in chronic tetraplegia versus 0.4 points...
Fennec Pharma, U. of Arizona Cancer Center Announce Study
Fennec Pharmaceuticals is backing a new investigator-sponsored Phase I/II trial at the University of Arizona Cancer Center evaluating intravenous...
ANI Pharma Publishes ‘New Day’ Ophthalmology Trial Results
Peer-reviewed publication of the randomized Phase 4 NEW DAY trial evaluating ILUVIEN (fluocinolone acetonide 0.19 mg intravitreal implant) as...
Minerva Screens First Patient in Phase 3 Schizophrenia Trial
Minerva Neurosciences has screened the first patient in MIN-101C19, a global, confirmatory Phase 3 trial of roluperidone as monotherapy...
Trethera & MGH Launch Clinical Trial for TRE-515 in ALS
In Trethera’s prior expanded access case, treatment with TRE-515 in an 87-year-old patient with advanced ALS was associated with...
Ernexa Therapeutics Advances Toward 2026 Human Trials
Preclinical data from a syngeneic ovarian cancer model showed that Ernexa’s ERNA-101, an engineered induced mesenchymal stem cell therapycell...
Bio Solutions’ Successful Study Advances FDA Drug Screening
Intelligent Bio Solutions completed its initial clinical Cut-off Study for a fingerprint-based codeine screen in 40 adults, finalizing data...
Adagene, Incyte Collaborate on Colorectal Cancer Drug Trial
No new efficacy data accompanied the announcement. Prior signals for the components remain preliminary: muzastotug has shown encouraging responses...
Improved Durability Seen for Muzastotug Combo in CRC Study
Topline data from Adagene’s Phase 1b/2 trial in late-line MSS metastatic colorectal cancer without liver metastases show a dose-dependent...